Results 221 to 230 of about 1,015,413 (298)
Long-term care insurance in China: Current challenges and recommendations. [PDF]
Chen S +9 more
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Did the COVID-19 pandemic increase the long-term care insurance certification rate in Japan? An interrupted time-series analysis. [PDF]
Seino S +5 more
europepmc +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Improving healthcare efficiency through long-term care insurance (LTCI): a super-SBM and DID analysis of 291 Chinese cities. [PDF]
Jin T, Halili A.
europepmc +1 more source
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran +5 more
wiley +1 more source
Shaping Long-term Care Insurance Intentions Among Chinese Adults Aged 50-70: Role of Information Interventions in Health Risks. [PDF]
Liu J +5 more
europepmc +1 more source
Abstract Aim Individual second‐generation antihistamines may possess differential sedative potential due to the variability in central histamine receptor H1 occupancy. This study aimed to evaluate whether the sedative potential of second‐generation antihistamines is associated with the risk of injury during Japan's pollen season. Methods We conducted a
Jumpei Taniguchi +3 more
wiley +1 more source

